Pantop%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. ## Primary Indications * Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis * Zollinger-Ellison syndrome and other conditions of gastric hypersecretion * H. pylori eradication (in combination with antibiotics) ## Adult Dosing * **GERD (symptomatic relief):** 20 mg orally once daily. * **GERD (healing erosive esophagitis):** 40 mg orally once daily for 4 to 8 weeks. * **Maintenance of healing:** 20 mg orally once daily. * **Zollinger-Ellison Syndrome:** 40 mg orally twice daily, may be increased to a maximum of 240 mg daily in divided doses. * **H. pylori eradication:** 40 mg orally twice daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily for 7 days, OR pantoprazole 40 mg orally twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 7 days. Intravenous dosing: * **GERD and erosive esophagitis healing:** 40 mg IV once daily for up to 7 days. * **Zollinger-Ellison Syndrome:** 40 mg IV every 12 hours, may be increased to 80 mg IV every 8 hours. ## Pediatric Dosing * **GERD (erosive esophagitis):** * 1-5 years: 10 mg orally once daily for up to 8 weeks. * 6-11 years: 20 mg orally once daily for up to 8 weeks. * 12-17 years: 40 mg orally once daily for up to 8 weeks. * **GERD (symptomatic relief):** * 5-11 years: 10 mg orally once daily. * 12-17 years: 20 mg orally once daily. IV dosing in pediatric patients is less established and should be guided by specific institutional protocols or specialist consultation. ## Dose Adjustments * **Hepatic Impairment:** For oral formulations, consider reducing the dose to 20 mg once daily. IV dosing may also require reduction. * **Renal Impairment:** No dose adjustment is typically needed. ## Contraindications * Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness. * **Serious:** Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, Vitamin B12 deficiency, systemic lupus erythematosus (cutaneous and systemic), fundic gland polyps. ## Key Drug Interactions * **Drugs dependent on gastric pH for absorption:** Clopidogrel (reduced efficacy), certain antifungals (ketoconazole, itraconazole), certain HIV protease inhibitors. Separate administration times or consider alternatives. * **Methotrexate:** PPIs may increase methotrexate levels; monitor for toxicity. * **CYP2C19 substrates:** Monitor for altered effects. ## Monitoring * Monitor for signs and symptoms of C. difficile infection. * Monitor serum magnesium levels, especially with prolonged use (≥3 months). * Assess for bone fracture risk with long-term PPI therapy. * Monitor B12 levels with prolonged therapy. ## Clinical Pearls * PPIs are most effective when taken 30-60 minutes before a meal. * Long-term use (>1 year) is associated with an increased risk of fractures, C. difficile infection, hypomagnesemia, and B12 deficiency. * Discontinuation should be considered gradually to avoid rebound acid hypersecretion. *** **Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to confirm dosing and safety for individual patients.